| 【Company Research】WuXi Biologics (2269 HK) - Expand overseas capacity to mitigate risks |
| 【公司研究】蒙牛乳业 (2319 HK) - 2H23不及预期，高品质发展目标延续 |
| 【Company Research】BYD (1211 HK) - Good FY23 earnings quality |
| 【Company Research】AK Medical (1789 HK) - The belated recovery will always come |
| 【Company Research】Ping An (2318 HK) - Resilient DPS despite OPAT decline; EV assumptions change cut VNB more than expected |
| 【Company Research】Weichai Power (2338 HK) - Key takeaways from post-results call |
| 【Company Research】Kelun-Biotech (6990 HK) - Intense data release to further validate the global potential of SKB264 |
| 【公司研究】巨子生物 (2367 HK) - 业绩超预期，持续发力线上渠道 |
| 【Company Research】Zhihu (ZH US) - Prioritizing breakeven target |
| 【Company Research】Weichai Power (000338 CH) - Key takeaways from post-results call |
公司地址：香港中环花园道三号冠君大厦45-46楼
电话：（852）3900-0888 传真：（852）3761-8788
招银国际版权所有 Copyright © 2019-2025 CMB International Capital Corporation Limited. All rights reserved.
